Navigation Links
Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Date:2/9/2009

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 21st Annual Roth OC Growth Stock Conference on Monday, February 16, 2009 at 1:00 p.m. PST (4:00 p.m. EST). The conference is being held at The Ritz-Carlton, Laguna Niguel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 2, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepat
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
2. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
3. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
4. Bacteria from sponges make new pharmaceuticals
5. Hypertension and cholesterol medications present in water released into the St. Lawrence River
6. Sea bed provides information about present climatic change
7. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
8. New manual presents robust, state-of-the-art proteomics methods for teaching and research
9. Hobbit fossils represent a new species, concludes University of Minnesota anthropologist
10. UAF researchers to present at AGU press briefing
11. New gene variants present opportunities in nutrigenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
... photosynthesis, it's good to think "outside the bun." , That's ... Arts & Sciences at Washington University in St. Louis, did ... his collaborators at Lawrence Berkeley National Laboratory and the University ... taco shell protein. , Taco shell protein ...
... "backup" brain region springs into action to compensate for disruption ... finding offers new insight into how the brains of stroke ... of movement. , Jacinta O'Shea and colleagues at the University ... issue of the journal Neuron, published by Cell Press. ...
... The antiviral drug peramivir might offer humans significant protection ... according to results of mouse studies conducted by investigators ... Peramivir, an antiviral drug, blocks the ability of influenza ... the release of new virus particles and their spread ...
Cached Biology News:Protein enables discovery of quantum effect in photosynthesis 2Protein enables discovery of quantum effect in photosynthesis 3How the brain's backup system compensates for stroke 2Peramivir protects mice from lethal H5N1 infection 2
(Date:3/3/2015)... SAN CARLOS, Calif. , March 3, 2015 /PRNewswire/ ... with expertise in drug-disease modeling and simulation research, today ... during the 2015 American Society for Clinical Pharmacology and ... March 3-7 2015.   Logo - ... and Rosa will present a poster describing a ...
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... FRANCISCO , March 3, 2015  Johnson & ... @ South San Francisco (JLABS @SSF), ... Boulevard, South San Francisco, Calif. ... accommodate up to 50 startups from across the healthcare ... health.  The first resident startups have ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5
... May 13 A guide to BRCA1 and ... resource is designed to equip physicians and other healthcare professionals who are ... the complexities of BRCA1/2 gene testing. , ... According to the American Cancer Society, ...
... TIANJIN, China , May 13 /PRNewswire-Asia/ -- A ... of,Biotechnology and Medicine (TJAB) and Genzyme Corporation was held in the,Tianjin ... , , ... executives including Rao Zihe, President of TJAB and,President of Nankai University, ...
... May 13  Fibrocell Science, Inc. (OTC Bulletin ... of autologous cell therapies for aesthetic, medical and scientific ... study (IT-H-001) of azficel-T, an autologous cell therapy currently ... (FDA) for the treatment of moderate to severe nasolabial ...
Cached Biology Technology:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 2Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 3
...
... Antibody Binding: High, 400 ng IgG/cm 2 ... Binding Interaction: Hydrophobic/Ionic , Performance Certified: Well-to-Well, ... , Maximum Well Volume: 360 µl , ... ,Features, Special optically clear polystyrene formulation ...
...
...
Biology Products: